Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound βE/β0-thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The βE-globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated βE-globin with partial instability. When this is compounded with a non-functional β0 allele, a profound decrease in β-globin synthesis results, and approximately half of βE/β0-thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe βE/β0-thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl−1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-bia…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, this response was associated with a relative increase in a dominant myeloid clone bearing a lentiviral vector insertion within the HMGA2 gene locus.”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“In the initial study of HSCs transduced with β-globin in patients with β-thalassemia, one patient with βE/β0-thalassemia achieved independence from transfusion [67].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“The relative clonal dominance at the HMGA2 locus that was initially observed in 1 patient in the LG001 study of the HPV569 vector spontaneously subsided while that patient maintained stable HbA T87Q levels.”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
In the citing paper
“The feasibility of the addition of a gene to autologous hematopoietic cells using a lentiviral vector was shown previously in a single patient with β-thalassemia who safely discontinued transfusions for more than 6 years with ongoing, sustained β A-T87Q -globin expression.14,20”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
MicroRNA maturation: stepwise processing and subcellular localization
Lee, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf476 · Cited by 2,478
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“To demonstrate that only one integrated vector provirus was present in cells with the HMGA2 IS, three qPCR experiments were simultaneously performed on the same genomic DNA preparation with primers specific for either (1) a ‘HIV gag packaging signal’ DNA sequence (common to all vector provirus regardless of IS); (2) t…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Chung, J. H., Whiteley, M., & Felsenfeld, G. (1993) · Cell · doi:10.1016/0092-8674(93)80052-g · Cited by 854
Lin28 promotes transformation and is associated with advanced human malignancies
Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T. L., Toffanin, S., O'Sullivan, M., Lu, J., Phillips, L. A., Lockhart, V. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.392 · Cited by 814
Long-Term Propagation of Distinct Hematopoietic Differentiation Programs In Vivo
Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee, S.-J., Brinkman, R., & Eaves, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.015 · Cited by 609
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
Self-citationMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567 · cited 1×
“Numbers along the top indicate blood progenitors from a b-thalassaemic control individual (1), patient P2’s blood progenitors 27 months posttransplantation showing a band consistent with truncated fusion protein of 135 amino acids (2), recombinant truncated (73 amino acids) (4) and fulllength (109 amino acids) (5) hum…”
Background
Cited by
Items 801–900 of 1,000
Alonso, L., González‐Vicent, M., Beléndez, C., Badell, I., Sastre, A., Rodríguez-Villa, A., Cortés, M. B., Hladun, R., & de Heredia, C. D. (2019) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.12.010 · Cited by 15
Lentiviral mediated gene delivery as an effective therapeutic approach for Parkinson disease
Kakoty, V., Sarathlal, K. C., Dubey, S. K., Yang, C. H., Kesharwani, P., & Taliyan, R. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135769 · Cited by 13
Bonner, M. A., Morales‐Hernández, A., Zhou, S., Ma, Z., Condori, J., Wang, Y., Fatima, S., Palmer, L. E., Janke, L. J., Fowler, S., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.013 · Cited by 11
Yabe, I. M., Truitt, L. L., Espinoza, D. A., Wu, C., Koelle, S., Panch, S. R., Corat, M. A. F., Winkler, T., Yu, K., Hong, S. G., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.009 · Cited by 11
“However, a single thalassemia patient receiving HSPCs transduced with an LV driving a hemoglobin gene from a strong erythroid-specicfic promoter/enhancer has shown prolonged but eventually transient clonal expansion of cells, linked to an LV insertion resulting in aberrant splicing and overexpression of the gene HMGA2.”
BackgroundWhitney, D., Shestopalov, I. A., Fincker, M., d′Anjou, M., Kral, K., Gayron, M., Pierciey, F. J., & Colvin, R. A. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101155 · Cited by 10
Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects
Jaballah, S. A., Ali, L. M., Jehad, M. A., Akhlaq, S., Rizvi, T. A., & Mustafa, F. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169473 · Cited by 10
Engineering Globin Gene Expression
Davis, R., Gurumurthy, A., Hossain, M. A., Gunn, E. M., & Bungert, J. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.004 · Cited by 11
“The first attempt of human gene therapy for a hemoglobin disorder occurred in the early 1980s.26,27 Almost 30 years later, this approach succeeded in a clinical trial in France.28 The field had to overcome several major obstacles including: (1) the development of efficient and safe procedures for the patient condition…”
BackgroundMethodInfluentialHematopoietic Stem Cell Gene Therapy: Progress on the Clinical Front
Cavazzana, M. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2504 · Cited by 10
“…gene therapy vectors (with their greater capacity to accommodate genes and their tissue-specific transcription factors) has even enabled a patient with beta thalassemia to gain a transfusion-independent phenotype (Naldini et al. , 1996; Pawliuk et al. , 2001; Cavazzana-Calvo et al. , 2010).”
Ikuta, T., Kurayanagi, Y., Odo, N., & Liu, S. M. (2013) · Journal of Blood Medicine · doi:10.2147/jbm.s54671 · Cited by 14
“Let”-ing go with clonal expansion?
Resar, L. M. S., & Brodsky, R. A. (2011) · Blood · doi:10.1182/blood-2011-04-346668 · Cited by 11
A Graph Based Framework to Model Virus Integration Sites
Fronza, R., Vasciaveo, A., Benso, A., & Schmidt, M. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.10.006 · Cited by 11
“As consequence of this perturbation, i.e. if vectors integrate into cellular genome positions where theexpression of animportant geneis dysregulated, the affected cell may step from the primary illness state to a secondary state.”
BackgroundNovel Immunotherapies for the Treatment of Melanoma
Gato, M., Arasanz, H., Blanco‐Luquin, I., Glaría, E., Arteta-Sanchez, V., Kochan, G. T., & Escors, D. (2016) · Immunotherapy · doi:10.2217/imt-2015-0024 · Cited by 10
Gene therapy: Myth or reality?
Fischer, A. (2016) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2016.04.011 · Cited by 11
Self-citationShaw, A., Joseph, G. L., Jasti, A. C., Sastry, L., Witting, S. R., & Cornetta, K. G. (2016) · Gene Therapy · doi:10.1038/gt.2016.69 · Cited by 11
Self-citationTargeting the niche: depleting haemopoietic stem cells with targeted therapy
Abadir, E., Bryant, C. E., Larsen, S. R., & Clark, G. J. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0445-0 · Cited by 11
Koblas, T., Leontovyč, I., Loukotová, Š., & Saudek, F. (2019) · Folia Biologica · doi:10.14712/fb2019065030109 · Cited by 11
“This limits potential clinical application of such reprogramming approaches (Hacein-Bey-Abina et al., 2003; Cavazzana-Calvo et al., 2010).”
BackgroundThe impact of clonal diversity and mosaicism on haematopoietic function in Fanconi anaemia
Hughes, A. D., & Kurre, P. (2021) · British Journal of Haematology · doi:10.1111/bjh.17653 · Cited by 10
Tsunogai, T., Ohashi, T., Shimada, Y., Higuchi, T., Kimura, A., Watabe, A. M., Kato, F., Ida, H., & Kobayashi, H. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.012 · Cited by 10
“In addition, in b-thalassemia treated with LV ex vivo gene therapy, clonal expansion was observed.(39) Recently, reports of the long-term efficacy of LV-mediated GT in XCGD mouse models have demonstrated that the clinical background of the original disease may play an important role in carcinogenicity rather than rand…”
BackgroundThe steep uphill path leading to ex vivo gene therapy for genodermatoses
Palamenghi, M., Luca, M. D., & Rosa, L. D. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00117.2022 · Cited by 11
Hladun, R., Elorza, I., Olivé, T., Dapena, J. L., Llort, A., de Toledo, J. S., & de Heredia, C. D. (2013) · Anales de Pediatría · doi:10.1016/j.anpedi.2012.12.002 · Cited by 10
Chattong, S., Ruangwattanasuk, O., Yindeedej, W., Setpakdee, A., & Manotham, K. (2017) · Gene Therapy · doi:10.1038/gt.2017.42 · Cited by 10
Papadopoulou, L. C., Ingendoh‐Tsakmakidis, A., Mpoutoureli, C. N., Tzikalou, L. D., Spyridou, E. D., Gavriilidis, G. I., Kaiafas, G. C., Ntaska, A. T., Vlachaki, E., Panayotou, G., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00857 · Cited by 10
Innovative Therapies for Hemoglobin Disorders
Sii-Felice, K., Nègre, O., Brendel, C., Tubsuwan, A., Morel-à-l’Huissier, E., Filardo, C., & Payen, E. (2020) · BioDrugs · doi:10.1007/s40259-020-00439-6 · Cited by 10
Self-citationStem Cells: The Holy Grail of Regenerative Medicine
Singh, R. K., Gaikwad, S. M., Chatterjee, S., & Ray, P. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4372-7_2 · Cited by 13
“[176, 194] have discussed the health of the second patient who had become transfusion independent for a period of 21 months after transplantation.”
Host Factors in Retroviral Integration and the Selection of Integration Target Sites
Craigie, R., & Bushman, F. D. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch45 · Cited by 10
Self-citationLentiviral Vector Promoter is Decisive for Aberrant Transcript Formation
Scholz, S., Fronza, R., Bartholomae, C. C., Cesana, D., Montini, E., Kalle, C. V., Gil-Fariña, I., & Schmidt, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.162 · Cited by 10
Advances in gene therapy for hematologic disease and considerations for transfusion medicine
Reddy, O. L., Savani, B. N., Stroncek, D. F., & Panch, S. R. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.07.004 · Cited by 16
An Emerging Era of Clinical Benefit From Gene Therapy
Malech, H. L., & Ochs, H. D. (2015) · JAMA · doi:10.1001/jama.2015.2055 · Cited by 10
Blobel, G. A., Bodine, D., Brand, M., Crispino, J., de Bruijn, M. F. T. R., Nathan, D., Papayannopoulou, T., Porcher, C., Strouboulis, J., Zon, L., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.06.008 · Cited by 9
“Gene therapy has made noteworthy, albeit slow, progress and is being tested in clinical trials in a limited number of patients [13,14].”
Progress in skin gene therapy: From the inside and out
Osborn, M. J., Panda, S., Reineke, T. M., Tolar, J., & Nyström, A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.017 · Cited by 9
A lentiviral vector pseudotype suitable for vaccine development
Lopes, L. M., Dewannieux, M., Takeuchi, Y., & Collins, M. K. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1553 · Cited by 9
Globin vector regulatory elements are active in early hematopoietic progenitor cells
Cabriolu, A., Odak, A., Zamparo, L., Yuan, H., Leslie, C. S., & Sadelain, M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.028 · Cited by 10
“The first was the occurrence of a major clonal expansion in a thalassemia patient treated with the HPV569 vector (subsequently named BB305 after removing the cHS4 insulator(45)), which deregulated expression of the proto-oncogene HMGA2 in an early myeloid progenitor, increasing its expression through a combination of…”
BackgroundThe discovery and development of RNA-based therapies for treatment of HIV-1 infection
Chen, M. J., Gatignol, A., & Scarborough, R. J. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2117296 · Cited by 10
Gene Therapy for Cardiomyocyte Renewal: Cell Cycle, a Potential Therapeutic Target
Son, Y., & Zhu, W. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00625-y · Cited by 9
Klapwijk, J. C., Río-Espínola, A. D., Libertini, S., Collin, P., Fellows, M. D., Jobling, S., Lynch, A. M., Martus, H., Vickers, C. A., Zeller, A., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.033 · Cited by 9
“31,32 In these cases, disrupted splicing appears to have resulted in a truncated messenger RNA, which removed negative regulatory sequences and resulted in cell proliferation.”
Current translational and clinical practices in hematopoietic cell and gene therapy
DiGiusto, D. L., & Kiem, H. (2012) · Cytotherapy · doi:10.3109/14653249.2012.694420 · Cited by 11
“A similar study in β-thalassemia has demonstrated transfusion independence in a single adult subject 3 years following transplantation with HSPC modified by a lentiviral vector expressing adult β-globin under the control of the endogenous β-locus control region cloned into the vector (97).”
Safety and Efficacy of Retroviral and Lentiviral Vectors for Gene Therapy
Cesana, D., Volpin, M., Secanechia, Y. N. S., & Montini, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_2 · Cited by 14
Xian, Y., Xie, Y., Song, B., Ou, Z., Ouyang, S., Xie, Y., Yang, Y., Xiong, Z., Li, H., & Sun, X. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01765-w · Cited by 9
Lederer, C. W., Koniali, L., Buerki‐Thurnherr, T., Papasavva, P. L., Grutta, S. L., Licari, A., Štaud, F., Bonifazi, D., & Kleanthous, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040793 · Cited by 10
Drakopoulou, E., Georgomanoli, M., Lederer, C. W., Panetsos, F., Kleanthous, M., Voskaridou, E., Valakos, D., Papanikolaou, E., & Anagnou, N. P. (2022) · Viruses · doi:10.3390/v14122716 · Cited by 10
Podetz-Pedersen, K. M., Laoharawee, K., Singh, S. M., Nguyen, T. T. T. N., Smith, M. C., Temme, A., Kozarsky, K., McIvor, R. S., & Belur, L. R. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.162 · Cited by 9
“54 By comparison, the primary risk of AAV administration is immune response against the gene product or against the vector capsid, 55 which can be mitigated by controlling vector dose and patient monitoring to see if there is a need for immunomodulation.”
Scaling Up of Steric Exclusion Membrane Chromatography for Lentiviral Vector Purification
Labisch, J. J., Paul, R., Wiese, G. P., & Pflanz, K. B. (2023) · Membranes · doi:10.3390/membranes13020149 · Cited by 9
“The external mixing of PEG buffer with the LV solution and incubation could have led to LV aggregation as depletion interaction can occur between LVs and the stationary phase during the SXC loading step, as well as between the viral particles themselves [27].”
A systematic review of clinical trials for gene therapies for β-hemoglobinopathy around the world
Rós, F. A., Couto, S. C. F., Milhomens, J., Ovider, I., Tozatto‐Maio, K., Jennifer, V., Ramos, R. N., Picanço‐Castro, V., Kashima, S. H., Calado, R. T., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.05.006 · Cited by 10
Using Pulmozyme DNase Treatment in Lentiviral Vector Production
Shaw, A., Bischof, D., Jasti, A. C., Ernstberger, A. G., Hawkins, T., & Cornetta, K. G. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.204 · Cited by 9
“L entiviral vectors have shown promise as a new therapeutic tool for patients with life-threatening disorders (Levine et al. , 2006; Cartier et al. , 2009; Cavazzana-Calvo et al. , 2010; DiGiusto et al. , 2010; Kalos et al. , 2011).”
Self-citationAn overview of current treatment strategies for β-thalassemia
Cappellini, M. D., Viprakasit, V., & Taher, A. T. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.918503 · Cited by 10
Ge, Y., Kong, Z., Guo, Y., Tang, W. D., Guo, W., & Tian, W. (2012) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2012.04.017 · Cited by 9
Strategies for More Rapid Translation of Cellular Therapies for Children: A US Perspective
López-Sánchez, R. C., Silberstein, L. E., Lindblad, R., Welniak, L. A., Mondoro, T. H., & Wagner, J. E. (2013) · PEDIATRICS · doi:10.1542/peds.2012-3383 · Cited by 9
Yang, M., Büsche, G., Ganser, A., & Li, Z. (2013) · Annals of Hematology · doi:10.1007/s00277-012-1655-3 · Cited by 9
“granulomatous disease (CGD) [3], Wiskott-Aldrich syndrome (WAS) [4], adenosine deaminase deficiency (SCID-ADA) [5], and β-thalassemia [6].”
BackgroundEfficacy and Safety of Gene Therapy for β-Thalassemia
Payen, E. (2022) · New England Journal of Medicine · doi:10.1056/nejme2118580 · Cited by 9
Self-citationGenome Editing for the β-Hemoglobinopathies
Porteus, M. H. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-7299-9_8 · Cited by 8
An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA
Castracani, C. C., Breda, L., Papp, T. E., Guerra, A., Radaelli, E., Assenmacher, C., Finesso, G., Mui, B. L., Tam, Y. K., Fontana, S., et al. (2024) · Blood · doi:10.1182/blood.2024025846 · Cited by 9
Risk of cancer in patients with thalassemia and sickle cell disease: a systematic review
Merolle, L., Ghirotto, L., Schiroli, D., Balestra, G. L., Venturelli, F., Bassi, M. C., Bartolomeo, E. D., Baricchi, R., & Marraccini, C. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2522967 · Cited by 10
“Few patients have been treated with these innovative therapies to date [50–54], or, the follow-up is not long enough yet to draw conclusions concerning the incidence of cancers, which, as we know, may occur several years after therapy.”
Epigenetic Regulation of Erythropoiesis: From Developmental Programs to Therapeutic Targets
Vasiloudis, N.-I., Paschoudi, K., Beta, C., Georgolopoulos, G., & Psatha, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136342 · Cited by 9
“The first clinical trial for β -thalassemia [175] was performed using the Lentiglobin HPV569 vector, which contained a minimal β -globin promoter and the HS2, HS3, and HS4 elements.”
Watershed year of cell and gene therapy (CGT): A review of 2024 CGT approvals
Jian, A., Zhao, G., Wang, Y., Wang, S., & Li, N. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217980 · Cited by 10
Adaptation of lentiviral vectors for viral gene therapy and their impact on host cell biology
Kaiser, C. W., Rouchka, E. C., & Smith, M. L. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07626-5 · Cited by 9
“Another team investigating LVV delivery of functional β-globin for the treatment of β-thalassemia demonstrated LVV integrations into HMGA2 in 45% of transduced nucleated blood cells [60].”
Azul, M., Vital, E. F., Lam, W. A., Wood, D. K., & Beckman, J. D. (2022) · Translational research · doi:10.1016/j.trsl.2022.03.010 · Cited by 8
Pellaers, E., Bhat, A., Christ, F., & Debyser, Z. (2022) · Viruses · doi:10.3390/v15010032 · Cited by 8
“Although this integration pattern seems to be safer, lentiviral vectors come also with risks, as aberrant splicing [178,182] and clonal expansion [183] have been observed.”
BackgroundProgress in the field of hematopoietic stem cell-based therapies for inborn errors of immunity
Arnold, D. E., & Pai, S. (2023) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001292 · Cited by 8
Gene therapy strategies for RAG1 deficiency: Challenges and breakthroughs
Gilioli, G., Lankester, A. C., de Kivit, S., Staal, F. J. T., & de Bruin, L. M. O. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106931 · Cited by 9
Eshghi, S., Bakhtiari, M. M., Behfar, M., Izadi, E., Naji, P., Jafari, L., Mohseni, R., Saltanatpour, Z., & Hamidieh, A. A. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.12.007 · Cited by 9
“…said cryptic splicing can only happen in vectors containing the chicken hypersensitive site 4 (cHS4) insulator, an insulator sequence of the chicken b-like globin gene cluster, in their long terminal repeat (LTR), that can increase the random integration of the vector [36 e 39] (Table 1, Row No.3).”
Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec
Holzwarth, D., Calaminus, G., Friese, J., Sejersen, T., Büning, H., John-Neek, P., Bastone, A. L., Rothe, M., Mansfield, K. G., Libertini, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.025 · Cited by 9
“38,39 After transduction, rAAV vectors persist primarily as episomal DNA within the cell.”
Novel reporter systems for facile evaluation of I-SceI-mediated genome editing
Muñoz, N. M., Beard, B. C., Ryu, B. Y., Luche, R. M., Trobridge, G. D., Rawlings, D. J., Scharenberg, A. M., & Kiem, H. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr897 · Cited by 8
Zhang, W., Chen, H., Zheng, X., Wang, D., Ji, H., Xia, H., & Mao, Q. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.08.003 · Cited by 8
The therapeutic potential of genome editing for β-thalassemia
Glaser, A., McColl, B., & Vadolas, J. (2015) · F1000Research · doi:10.12688/f1000research.7087.1 · Cited by 9
Structural influence of graft and block polycations on the adsorption of BSA
Zhang, L., Jin, F., Zhang, T., Zhang, L., & Xing, J. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.12.088 · Cited by 8
RNA Trans-Splicing Targeting Endogenous β-Globin Pre-Messenger RNA in Human Erythroid Cells
Uchida, N., Washington, K. N., Mozer, B. A., Platner, C., Ballantine, J., Skala, L. P., Raines, L. N., Shvygin, A., Hsieh, M. M., Mitchell, L. G., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.077 · Cited by 8
“DISCUSSION In the current strategy in HSC-targeted gene therapy for SCD, a normal b-globin (or c-globin) gene is added to autologous HSCs, and the b-globin (or cglobin) is produced in red blood cells to prevent sickling.(5) On the other hand, the trans-splicing-based gene therapy has a potential major advantage in tha…”
Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy
Cowan, M. J., Dvorak, C. C., & Long-Boyle, J. R. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.003 · Cited by 8
Gene Therapy for Hemophilia A: Where We Stand
Zhou, M., Hu, Z., Zhang, C., Wu, L., Li, Z., & Liang, D. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200806110849 · Cited by 9
RNA splicing factor Rbm25 underlies heterogeneous preleukemic clonal expansion in mice
Bramlett, C. S., Eerdeng, J., Du, J., Lee, Y., Garcia, I., Vergel-Rodriguez, M., Condie, P., Nogalska, A., & Lu, R. (2023) · Blood · doi:10.1182/blood.2023019620 · Cited by 10
A self‐deletion lentiviral vector to reduce the risk of replication‐competent virus formation
Fang, Y., Gong, X., Xu, M., Zeng, F., & Zhang, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2700 · Cited by 8
Surface Modification of Retroviral Vectors for Gene Therapy
Metzner, C., & Dangerfiel, J. (2011) · InTech eBooks · doi:10.5772/20568 · Cited by 8
“…in the USA, recently completed 2 trials with three patients in total who underwent ex vivo treatment of their own hematopoietic stem cells with a LV vector delivering corrective genes for either cerebral adrenoleukodystrophy (Cartier et al. 2009) or beta-thalassaemia (Cavazzana-Calvo et al. 2010).”
BackgroundGene therapy: too much splice can spoil the dish
Trono, D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63066 · Cited by 9
Carbonaro-Sarracino, D. A., Tarantal, A. F., Lee, C. C. I., Martinez, M. L., Jin, X., Wang, X., Hardee, C. L., Geiger, S., Kahl, C. A., & Kohn, D. B. (2014) · Molecular Therapy · doi:10.1038/mt.2014.88 · Cited by 10
Gene therapy: Progress in childhood disease
Ginn, S. L., & Alexander, I. E. (2011) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2011.02204.x · Cited by 10
Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders
Trajanoska, K., & Rivadeneira, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.556610 · Cited by 9
“Allelic combinations of SOST, PTH, FDPS, and GGPS1 gene variants may also have a role in the individual response to bisphosphonate treatment (93).”
BackgroundInfluentialTargeted Lentiviral Vectors: Current Applications and Future Potential
Goyvaerts, C., Liechtenstein, T., Bricogne, C., Escors, D., & Breckpot, K. (2013) · InTech eBooks · doi:10.5772/52770 · Cited by 8
Zheng, Q., Zhang, X., Yang, H., Xie, J., Xie, Y., Chen, J., Yu, C., & Chen, Z. (2019) · Viruses · doi:10.3390/v11100920 · Cited by 9
Therapeutics in paediatric genetic diseases: current and future landscape
Koh, A. L., & Jamuar, S. S. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2021-376 · Cited by 8
Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
Dunbar, C. E. (2024) · New England Journal of Medicine · doi:10.1056/nejme2409399 · Cited by 8
Zeglinski, K., Montellese, C., Ritchie, M. E., Alhamdoosh, M., Vonarburg, C., Bowden, R. J., Jordi, M., Gouil, Q. A., Aeschimann, F., & Hsu, A. L. (2024) · Genome Research · doi:10.1101/gr.279405.124 · Cited by 11
“This insulator was previously shown to contain a potent cryptic splice acceptor site, which was identified as the cause for clonal dominance in progenitor and myeloid lineages of patients in clinical trials (Cavazzana-Calvo et al. 2010; De Ravin et al. 2022).”
InfluentialPreclinical development of lentiviral vector gene therapy for Diamond-Blackfan anemia syndrome
Bhoopalan, S. V., Mayuranathan, T., Liu, N., Mayberry, K. D., Yao, Y., Zhang, J., Métais, J., Yan, K., Throm, R. E., Ellis, S. R., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.020 · Cited by 8
“13,29,30 Those cases were caused by a dominant SA in the cHS insulator element, which is not present in SJEFS-S19 LV. 29 In silico analysis identi fi ed fi ve potential SAs in the protein coding region of SJEFS-S19 LV (Figure 5A).”
He, H., He, Z., Lund, S. P., Turner, L., Fan, Y., Qiu, Y. F., Corney, D. C., Dropulić, B., Orentas, R. J., Slessareva, O., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101472 · Cited by 7
Li, Y., Liu, Z., Wang, W., Li, J., Zhao, J., Xian, C. J., & Zhai, Y. (2025) · RSC Advances · doi:10.1039/d5ra06586k · Cited by 8
Improved functionality and potency of next generation BinMLV viral vectors toward safer gene therapy
Looveren, D. V., Giacomazzi, G., Thiry, I., Sampaolesi, M., & Gijsbers, R. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.07.003 · Cited by 8
“Indeed, SIN viral vector designs still induced oncogene activation in in-vitro safety assays and resulted in a dominant myeloid clone in a b-thalassemia clinical trial.(6,26,27) However, replacing the potent viral promoters for a weaker cellular version, like elongation factor 1a (EF1a) and phosphoglycerate kinase (PG…”
BackgroundStibbs, D. J., Couto, P. S., Takeuchi, Y., Rafiq, Q. A., Jackson, N. B., & Rayat, A. C. M. E. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101264 · Cited by 10
“1,2 5 However, their prohibitive costs may preclude the widespread adoption of these therapies.”
Qin, W., Zhu, H., Chen, L., Xiaoting, Y. A. N. G., Huang, Q., & Lin, Z. (2014) · Dental Materials Journal · doi:10.4012/dmj.2014-109 · Cited by 7
Alternative Splicing Caused by Lentiviral Integration in the Human Genome
Moiani, A., & Mavilio, F. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00008-9 · Cited by 7
Advancing the care of β-thalassaemia patients with novel therapies.
Bou‐Fakhredin, R., Motta, I., & Cappellini, M. D. (2022) · Blood transfusion · doi:10.2450/2021.0265-21 · Cited by 10
Pseudotyped Viruses for Retroviruses
Solomon, M., & Liang, C. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-0113-5_4 · Cited by 7
Handgretinger, R., & Mezger, M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2399134 · Cited by 9
“Indeed, the high volume of semi-random integration sites by the lentivirus and the transactivation of the proto-oncogene HMGA2 have been seen which could cause leukemia and might be a safety concern [26,27].”
Mechanisms of Oncogenesis by Avian and Murine Retroviruses
BEEMON, K. L., & Rosenberg, N. E. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0016-5_27 · Cited by 7
Cancer Gene Therapy: The New Targeting Challenge
Touati, W., Beaune, P. H., & de, I. (2011) · InTech eBooks · doi:10.5772/24788 · Cited by 7
“…to use CPA treatment in combination with additional prodrugs known to be activated to cytotoxic metabolites under hypoxic conditions, such as AQ4N by CYP 2B6 or mitomycin C and tirapazamine by RED (J. M. Brown & Wang, 1998; Cavazzana-Calvo et al., 2010; Friery et al., 2000; McErlane et al., 2005).”
BackgroundMethodUchida, N., Hsieh, M. M., Platner, C., Saunthararajah, Y., & Tisdale, J. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104022 · Cited by 7
“Viral vectors achieve their therapeutic effect by integrating into genomic DNA of target cells to stably express a desired gene, but these vectors have a potential risk of mutagenesis by inserting into or near cellular oncogenes [3,5,8,9].”
Field, A.-C., & Qasim, W. (2015) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2015.14 · Cited by 7
Hanoun, N., Gayral, M., Pointreau, A., Buscail, L., & Cordelier, P. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.151 · Cited by 9
Badawy, S. M., & Thompson, A. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-30352-9_5 · Cited by 7
Nualkaew, T., Jearawiriyapaisarn, N., Hongeng, S., Fucharoen, S., Kole, R., & Svasti, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-43964-3 · Cited by 7
Miliotou, Α. N., Papagiannopoulou, D., Vlachaki, E., Samiotaki, M. K., Laspa, D., Theodoridou, S., Tsiftsoglou, A. S., & Papadopoulou, L. C. (2021) · Journal of Biological Research - Thessaloniki · doi:10.1186/s40709-021-00148-3 · Cited by 7
Episomes and Transposases—Utilities to Maintain Transgene Expression from Nonviral Vectors
Kreppel, F., & Hagedorn, C. (2022) · Genes · doi:10.3390/genes13101872 · Cited by 8
Nondividing Cells: A Safer Bet for Integrating Vectors?
Brady, T., & Bushman, F. D. (2011) · Molecular Therapy · doi:10.1038/mt.2011.40 · Cited by 8
Self-citation
Metadata
- Authors
- Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., Cavallesco, R., Gillet-Legrand, B., Caccavelli, L., Sgarra, R., Maouche-Chrétien, L., Bernaudin, F., Girot, R., Dorazio, R., Mulder, G.-J., Polack, A., Bank, A., Soulier, J., Larghero, J., Kabbara, N., Dalle, B., Gourmel, B., Socie, G., Chrétien, S., Cartier, N., Aubourg, P., Fischer, A., Cornetta, K., Galacteros, F., Beuzard, Y., Gluckman, E., Bushman, F., Hacein-Bey-Abina, S., & Leboulch, P.
- Affiliations
- Inserm (FR)
- University of Pennsylvania (US)
- Brigham and Women's Hospital (US)
- University of Trieste (IT)
- Hôpital Intercommunal de Créteil (FR)
- Hôpital Tenon (FR)
- Columbia University Irving Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Indiana University Indianapolis (US)
- Corresponding author
- Leboulch, Philippe
- ORCID
- Venue
- Nature
- Published
- 2010-09
- Volume
- 467
- Issue
- 7313
- Pages
- 318-322
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3355472
- OpenAlex
- W2136274459
- Cited by
- 1,276
- References
- 32
- Citations by year
- 2026: 14 · 2025: 45 · 2024: 46 · 2023: 53 · 2022: 64 · 2021: 75 · 2020: 76 · 2019: 84 · 2018: 79 · 2017: 97 · 2016: 94 · 2015: 99 · 2014: 94 · 2013: 116 · 2012: 106
- FWCI
- 63.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL090921, HL090921)
- National Institute of Allergy and Infectious Diseases (AI52845, R01AI082020, R01AI052845, AI082020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- beta-thalassemia, gene therapy, lentiviral vectors, transfusion independence, HMGA2, leukemia risk, hemoglobinopathies, sickle cell disease, hematopoietic stem cells, alternative splicing, hemoglobin
- MeSH terms
- Adolescent, Blood Cells, Blood Transfusion, Bone Marrow Cells, Child, Preschool, Clone Cells, Genetic Vectors, Homeostasis, Humans, Male, Organ Specificity, RNA, Messenger, Time Factors, Genetic Therapy, Transcriptional Activation, Gene Expression, Lentivirus, beta-Thalassemia, HMGA2 Protein, MicroRNAs, beta-Globins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.